214470-55-0

Basic information

• Product Name: 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE
• Synonyms: 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE ;4-Chloro-3-cyano-6,7-dimethoxyquinoline;3-Quinolinecarbonitrile, 4-chloro-6,7-diMethoxy-; 214470-55-0
• CAS NO: 214470-55-0
• Molecular Formula: C₁₂H₉ClN₂O₂
• Molecular Weight: 248.66506
• Mol File: 214470-55-0.mol

Chemical Properties

• Melting Point: 220-223 °C
• Boiling Point: 404.22 °C at 760 mmHg
• Flash Point: 198.266 °C
• Appearance: /
• Density: 1.361 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.621
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.68±0.41(Predicted)
• CAS DataBase Reference: 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE(214470-55-0)
• EPA Substance Registry System: 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE(214470-55-0)

Safety Data

• Hazardous Substances Data: 214470-55-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE is used as a reactant in the synthesis of Src kinase activity inhibitors. Src kinases are non-receptor tyrosine kinases that play a crucial role in various cellular processes, including cell proliferation, survival, and migration. Inhibition of Src kinase activity has been shown to have therapeutic potential in the treatment of various diseases, such as cancer and inflammatory disorders.
As a reactant in the synthesis of Src kinase inhibitors, 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE contributes to the development of novel therapeutic agents that can modulate the activity of these kinases, thereby providing potential treatment options for patients suffering from diseases associated with abnormal Src kinase activity.
Additionally, due to its unique structural features, 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE may also find applications in other areas of the pharmaceutical industry, such as the development of new drugs targeting different biological pathways or as a building block for the synthesis of other bioactive compounds.
Used in Chemical Industry:
In the chemical industry, 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE may be utilized as an intermediate in the synthesis of various organic compounds, including those with potential applications in materials science, agrochemicals, and other specialty chemicals. Its unique structural features make it a valuable building block for the development of new molecules with specific properties and functions.
Furthermore, the compound's reactivity and functional groups can be exploited in various chemical reactions, such as substitution, addition, and condensation reactions, to produce a wide range of derivatives with diverse applications in the chemical industry.

Synthesis Reference(s)

Journal of Medicinal Chemistry, 43, p. 3244, 2000 DOI: 10.1021/jm000206a

InChI:InChI=1/C12H9ClN2O2/c1-16-10-3-8-9(4-11(10)17-2)15-6-7(5-14)12(8)13/h3-4,6H,1-2H3

Upstream product

• 50845-31-3 4-hydroxy-6,7-dimethoxy-quinoline-3-carbonitrile 
• 214470-52-7 1,4-dihydro-6,7-dimethoxy-4-oxo-quinoline-3-carbonitrile 
• 30199-65-6 2-cyano-3-(3,4-dimethoxyphenylamino)acrylic acid ethyl ester 
• 6315-89-5 3,4-dimethoxyaniline 
• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 67-56-1 methanol 
• 263149-10-6 4-chloro-7-hydroxy-6-methoxyquinolin-3-carbonitrile 

Downstream Products

• 214486-09-6 4-(3-aminophenylamino)-6,7-dimethoxy-3-quinolinecarbonitrile 

Relevant articles and documents

PHOSPHODIESTERASE INHIBITORS AND USE

The invention provides compounds that may inhibits to ENPP1, and are accordingly useful for treatment disorders related to ENPP1. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent disorders related to ENPP1.

Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases

This study describes the discovery of novel dengue virus inhibitors targeting both a crucial viral protein-protein interaction and an essential host cell factor as a strategy to reduce the emergence of drug resistance. Starting from known c-Src inhibitors

3-AMINOTHIENO[3,2-c]QUINOLINE DERIVATIVES, METHODS OF PREPARATION AND USES

The present invention relates to compounds according to Formula I: and salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, and Y are as defined herein. Methods for preparing co

An efficient synthesis of dibenzo[c,f]-2,7-naphthyridine ring system through design of experiments

The dibenzo[c,f]-2,7-naphthyridine ring system was found to be of biological interest, but had limited synthetic accessibility. The initial compound of interest, 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3, 6-diamine, was obtained in 25% yie

Dibenzonaphthyridine derivatives and methods of use thereof

The present invention relates to Dibenzonaphthyridine Derivatives, compositions comprising an effective amount of a Dibenzonaphthyridine Derivative and methods for treating or preventing a proliferative disorder, comprising administering to a subject in need thereof an effective amount of a Dibenzonaphthyridine Derivative.

AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS

The invention is directed to aminoquinoline and aminoquinazoline compounds of Formula I: where R1, R2, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors

Synthesis and structure-activity relationship of a series of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitrile derivatives as EGFR inhibitors is described. Compounds 29 and 30 showed potent in vitro inhibitory activity in the enzymatic assay as well as in the functional cellular assay. They are moderately selective against other types of tyrosine kinases.

SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminoquinoline and aminoquinazoline compounds of Formula I′: where R1, R2, R3, B, Z, Q, p, q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Derivatives of quinoline as inhibitors for MEK

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof. wherein: n is 0-1; X and Y are independently selected from -NH-, -O-, -S-, or -NR8- where R8 is alkyl of 1-6 carbon atoms and X may additionally comprise a CH2 group; R7 is a group (CH2)mR9 where m is 0,or an integer of from 1-3 and R9 is a substituted aryl group, an optionally substituted cycloalkyl ring of up to 10 carbon atoms, or an optionally substituted heterocyclic ring or an N-oxide of any nitrogen containing ring; R6 is a divalent cycloalkyl of 3 to 7 carbon atoms, which may be optionally further substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a divalent pyridinyl, pyimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally further substituted with one or more specified groups; R1, R2, R3 and R4 are each independently selected from hydrogen or various specified organic groups. Compounds are useful as pharmaceuticals for the inhibition of MEK activity.